secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001753926-24-000411
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity
--------------------------------------------------------------------------------

- NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.
- Disclosed semaglutide as API in NPM-139, a once-yearly implant for chronic weight management.
- Strategic shift to prioritize obesity implants; NPM-115 designed for twice-yearly dosing.
- IND for NPM-119 (type 2 diabetes) on clinical hold; expects to submit CMC info to FDA in H1 2024.
- Plans to submit IND for NPM-115 first-in-human obesity study later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/0001753926-24-000411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/g084078_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-000411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer